TCRT Stock Explodes As Velaris Deal And $350M Raise Reset Outlook

Alaunos Therapeutics Inc. stocks have been trading up by 26.08 percent following highly positive sentiment around its cancer pipeline.

Live Update At 07:47:09 EDT: On Friday, October 16, 2026 Alaunos Therapeutics Inc. stock [NASDAQ: TCRT] is trending up by 26.08%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TCRT has flipped from a slow‑bleed biotech to a momentum rocket on the chart. For weeks, Alaunos Therapeutics Inc. sat under $1, closing at $0.79–$1.05 in early 2026/09 and 2026/10. That’s classic forgotten‑microcap territory.

Then the Velaris news hit. On 2026/10/12, TCRT closed at $1.05. By 2026/10/13, it spiked intraday to $4.32 and finished at $3.03. The next two days stayed wild, with closes at $2.07 and $2.18. That’s a multi‑hundred‑percent move in three sessions, with big wicks and wide ranges that scream day‑trading playground, not quiet swing.

Intraday 5‑minute data show TCRT churning between roughly $2.70 and $3.20 with tight, heavy trading — a sign the float is actively flipping between short‑term traders rather than drifting.

Fundamentally, Alaunos is still early‑stage. Last quarter, revenue was just $5,000, with a net loss of about $952,000 and free cash flow of around ‑$300,000. The current ratio sits at 0.8 and working capital is negative, which explains why the $350M raise is such a big deal. For traders, the story now is less about old financials and more about how long that fresh cash and new pipeline can keep momentum alive.

Why Traders Are Watching TCRT After The Velaris Deal

TCRT is suddenly on every biotech momentum watchlist, and there’s a clear reason why. Alaunos Therapeutics Inc. didn’t just issue a random press release — it completed a full pivot with the Velaris Therapeutics acquisition. That deal drops an entire pipeline of ActRII‑Fc ligand traps and biologics into Alaunos, focused on pulmonary arterial hypertension and related cardiopulmonary diseases. In one move, TCRT went from a tiny, struggling name to a reloaded pipeline story.

The twist that really woke up trading? The $350M private placement done alongside the deal. Alaunos sold Series C non‑voting convertible preferred stock, raising enough capital to stretch its cash runway into 2029. For a company that previously ended the quarter with just $124,000 in cash and negative working capital, that’s a total reset of the balance‑sheet risk. Near‑term financing fear — usually a killer overhang in micro‑cap biotech — is pushed way out.

Traders also care about catalysts. Management now has the funding to push VLR199 for pulmonary arterial hypertension through proof‑of‑concept and initial regulatory filings, along with several other Velaris‑sourced candidates. That means more news shots on goal over the next few years.

The price action confirms how the market is reading it. TCRT ran about 126% on heavy volume right after the announcement, and another report pegged the rally at roughly 225% on extremely heavy trading. That kind of move is a magnet for momentum players and short sellers. Alaunos Therapeutics Inc. has become a classic event‑driven, high‑beta trade: huge upside swings, but just as much downside if the crowd shifts.

Conclusion

For active traders, TCRT is now a textbook case of how fast sentiment can flip when a micro‑cap biotech lands a real deal and real capital. Alaunos Therapeutics Inc. took a weak balance sheet — $124,000 in cash, negative working capital, tiny revenue — and plugged it with a $350M private placement that funds operations into 2029. At the same time, it bolted on Velaris Therapeutics, gaining a focused cardiopulmonary pipeline with VLR199 as a lead pulmonary arterial hypertension asset.

The market’s reaction has been loud. Multi‑day surges of 126% to around 225%, huge intraday ranges, and relentless 5‑minute churn show TCRT has turned into a momentum battleground. On one side, you have traders chasing a newly funded pipeline and clear catalyst path. On the other, you have the overhang of future dilution from the convertible preferred stock and the reality that Alaunos still has to deliver clinical data.

This is not trading advice, but the trading lesson is clear. In Tim Sykes’ words, “Volatility is a gift if you respect it and a disaster if you don’t.” As millionaire penny stock trader and teacher Tim Sykes says, “Consistency is key in trading; don’t let emotions dictate your trades.”. TCRT now fits that mold perfectly — a high‑risk, high‑volatility biotech where disciplined traders will map levels, size small, and be ready to cut losses fast if the narrative cracks.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks